User profiles for Thomas Pfister

THOMAS D. PFISTER

Scientist
Verified email at fluidigm.com
Cited by 1697

Engineering novel metalloproteins: design of metal-binding sites into native protein scaffolds

Y Lu, SM Berry, TD Pfister - Chemical reviews, 2001 - ACS Publications
Proteins play an essential role in biology. Whether it is in catalysis or molecular recognition,
proteins set a golden standard of efficiency and selectivity that few other natural or artificial …

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

AC Tissot, P Maurer, J Nussberger, R Sabat, T Pfister… - The Lancet, 2008 - thelancet.com
Background Hypertension can be controlled adequately with existing drugs such as
angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Nevertheless, …

[PDF][PDF] CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells

…, U Lässing, RR Beerli, K Dietmeier, L Ivanova, T Pfister… - Immunity, 2005 - cell.com
Dendritic cells (DCs) are key instigators of adaptive immune responses. Using an alphaviral
expression cloning technology, we have identified the chemokine CCL19 as a potent …

A site-selective dual anchoring strategy for artificial metalloprotein design

JR Carey, SK Ma, TD Pfister, DK Garner… - Journal of the …, 2004 - ACS Publications
Introducing nonnative metal ions or metal-containing prosthetic groups into a protein can
dramatically expand the repertoire of its functionalities and thus its range of applications. …

Structural and functional characterization of the poliovirus replication complex

K Bienz, D Egger, T Pfister, M Troxler - Journal of virology, 1992 - Am Soc Microbiol
Two populations of membrane-bound replication complexes were isolated from poliovirus-infected
HEp-2 cells by sucrose gradient centrifugation. The two fractions show similar …

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

…, K Sladko, K Roubicek, T Pfister… - Journal of …, 2007 - journals.lww.com
Background Despite the availability of efficacious drugs, the success of treating hypertension
is limited by patients' inconsistent drug intake. Immunization against angiotensin II may …

[HTML][HTML] Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication

T Pfister, E Wimmer - Journal of Biological Chemistry, 1999 - ASBMB
The highly conserved non-structural protein 2C of picornaviruses is involved in viral genome
replication and encapsidation and in the rearrangement of intracellular structures. 2C binds …

ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses

R Jossé, SE Martin, R Guha, P Ormanoglu, TD Pfister… - Cancer research, 2014 - AACR
Camptothecin and its derivatives, topotecan and irinotecan, are specific topoisomerase I (Top1)
inhibitors and potent anticancer drugs killing cancer cells by producing replication-…

[PDF][PDF] Nailfold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: a multicenter, prospective cohort study

…, H Chadha‐Boreham, E Cottreel, T Pfister… - Arthritis & …, 2016 - Wiley Online Library
Objective To identify nailfold videocapillaroscopic features and other clinical risk factors for
new digital ulcers (DUs) during a 6‐month period in patients with systemic sclerosis (SSc). …

Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

TD Pfister, WC Reinhold, K Agama, S Gupta… - Molecular cancer …, 2009 - AACR
Topoisomerase I (Top1) is a proven target for cancer therapeutics, and the level of Top1 in
tumors has been used as a biomarker for chemotherapeutic efficacy. In this study, we report …